Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

halt-RONIN

Financiado

Cerrado

Discovering chronic inflammation biomarkers that define key stages in the Health...

Discovering chronic inflammation biomarkers that define key stages in the Healthy to NASH non alcoholic steatohepatitis transition to inform early prevention and treatment strategies Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease that is prevalent in 1 of 4 individuals with a significant personal, socioeconomic and healthcare burden, especially at the later, more sev... ver más

30/11/2026

UCM

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

Universidad Complutense de Madrid No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 3281

Fecha límite participación Sin fecha límite de participación.

Ver 24 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-22

HORIZON-HLTH-2022-STAYHLTH-02-01: Personalised blueprint of chronic i... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

24 Participantes

UCM

815.65K€ | Lider

IZMIR BIOMEDICINE AND GENOME...

335.95K€ | Participante

UNIVREN

42.72K€ | Participante

ANAXOMICS BIOTECH

373.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

mtFOIE GRAS mitoFOIE GRAS Non invasive Profiling of Mitochondrial Funct... 455K€ Cerrado

LITMUS Liver Investigation Testing Marker Utility in Steatohepatit... 47M€ Cerrado

Foie Gras Bioenergetic Remodeling in the Pathophysiology and Treatment... 3M€ Cerrado

SAF2017-85877-R INVESTIGACION TRASLACIONAL EN ESTEATOHEPATITIS NO ALCOHOLICA... 182K€ Cerrado

MacinNASH Revealing the contribution of liver macrophage populations t... 2M€ Cerrado

BARINAFLD Using Bariatric Surgery to Discover Weight Loss Independent... 1M€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2022-11-22
Fecha Fin: 2026-11-30

Líder del proyecto

Universidad Complutense de Madrid No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 3281

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Non-alcoholic fatty liver disease (NAFLD) is a multifactorial chronic inflammatory disease that is prevalent in 1 of 4 individuals with a significant personal, socioeconomic and healthcare burden, especially at the later, more severe inflammatory stage of disease - non-alcoholic steatohepatitis (NASH). Despite the severe negative impact of the disease on society, NAFLD remains difficult to diagnose and treat. Additionally, the molecular mechanisms underlying the transition from health to fatty liver to NASH remain poorly understood due to the lack of models that faithfully reflect the complexity of human disease. Hence, Halt-RONIN aims to uncover the early triggers of disease initiation and complex mechanistic drivers of disease progression by implementing a systems biology approach with integrative disease modelling resulting in opportunities for the improvement of the existing detection methods, providing a blueprint to inform personalized intervention strategies and drug discovery for NAFLD. To achieve this goal, Halt-RONIN will combine experimental data from advanced in vitro and in vivo models with multimodal data from extensive human NAFLD cohorts and biobanks and use in silico machine learning approaches, to discover new biomarkers and molecular targets specific to each stage of the health-to-disease transition. By validating preclinical experimental findings with real-world data, RONIN will allow for the discovery of novel biomarkers and molecular targets that are specific to the individual patient’s pathology. Consequently, healthcare professionals will gain the tools and knowledge required to diagnose and establish guidelines for the prevention and treatment of inflammation-driven health to disease. As such, in the long-term RONIN will decrease the number of NAFL patients who progress into NASH and provide disease-modifying strategies to improve patient outcomes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores